Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPGREIL, R.KATO, K.AJANI, J.DOKI, Y.XU, J.WYRWICZ, L.MOTOYAMA, S.OGATA, T.KAWAKAMI, H.HSU, C. -HADENIS, A.HAJBI, F. ElBARTOLOMEO, M. DiBRAGHIROLI, M. IgnezHOLTVED, E.MURPHY, M. BlumPATEL, A.HU, N.MATSUMURA, Y.CHAU, IKITAGAWA, Y.2024-03-082024-03-082023ONCOLOGY RESEARCH AND TREATMENT, v.46, suppl.5, p.242-243, 20232296-5270https://observatorio.fm.usp.br/handle/OPI/58519engrestrictedAccessNivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648conferenceObjectCopyright KARGEROncology2296-5262